60,638 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Spear Holdings RSC Ltd

Spear Holdings RSC Ltd acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 60,638 shares of the medical research company’s stock, valued at approximately $29,805,000. Thermo Fisher Scientific comprises approximately 3.0% of Spear Holdings RSC Ltd’s investment portfolio, making the stock its 14th biggest holding.

Several other large investors also recently bought and sold shares of the stock. Legacy Wealth Managment LLC ID boosted its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. High Note Wealth LLC lifted its stake in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $28,000. Finally, Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, ahead of the $5.71 consensus, with revenue of $11.99 billion also topping estimates. Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today
• Positive Sentiment: Management raised full-year FY2026 guidance, with EPS and revenue outlooks both coming in above Wall Street expectations, signaling confidence in continued demand and execution. Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights
• Positive Sentiment: Improving customer activity across end markets and continued organic growth helped ease investor concerns about a prolonged slowdown in medical research and tools demand. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Separately, Thermo Fisher was selected by ImmuPharma to help manufacture its Kapiglucagon diabetes candidate, a modest business development update that supports the company’s CDMO pipeline but is not likely to move shares on its own. ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 8.9%

Shares of Thermo Fisher Scientific stock opened at $573.43 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a market capitalization of $213.10 billion, a P/E ratio of 31.52, a PEG ratio of 2.33 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company’s fifty day moving average is $491.42 and its two-hundred day moving average is $513.08.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TMO shares. Morgan Stanley reiterated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $606.45.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.